Platelet endothelial cell adhesion molecule‑1 gene 125C/G polymorphism is associated with deep vein thrombosis

Li,Gang; Han,Zong‑Lin; Dong,He‑Gui; Zhang,Xia; Kong,Xiang‑Qian; Jin,Xing

doi:10.3892/mmr.2015.3586

Platelet endothelial cell adhesion molecule‑1 gene 125C/G polymorphism is associated with deep vein thrombosis

Authors:
- Gang Li
- Zong‑Lin Han
- He‑Gui Dong
- Xia Zhang
- Xiang‑Qian Kong
- Xing Jin
View Affiliations

Affiliations: Department of Vascular Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Department of General Surgery, The Central Hospital of Tai'an, Tai'an, Shandong 271000, P.R. China
Published online on: April 1, 2015 https://doi.org/10.3892/mmr.2015.3586
Pages: 2203-2210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deep vein thrombosis (DVT) is a common disorder that is associated with high morbidity and mortality. Genetic factors have been suggested to influence the predisposition towards thrombosis and the incidence of DVT. Platelet endothelial cell adhesion molecule‑1 (PECAM‑1) is a key adhesion molecule that is involved in platelet function and maintenance of endothelial cell junctions. To date, no studies have examined the association between polymorphisms in PECAM‑1 and DVT. The present study analyzed the single nucleotide polymorphisms (SNPs) of PECAM‑1, namely Leu125Val (C373G), Asn563Ser (T1688C) and Gly670Arg (C2008T), in Chinese patients with DVT and age‑ and gender‑matched controls, using polymerase chain reaction‑restriction fragment length polymorphism analysis. Furthermore, plasma soluble PECAM‑1 (sPECAM‑1) levels were quantified by ELISA. The results of the present study demonstrated significantly higher genotype and allele frequencies of the Leu125Val polymorphism in PECAM‑1 in the DVT group as compared with those in the control group (P<0.05). The plasma levels of sPECAM‑1 in the DVT group (83.4±23.5 ng/ml) were also significantly higher as compared with those in the control group (60.4±19.4 ng/ml, P<0.01). In the patients with DVT, plasma levels of sPECAM‑1 were significantly higher in those with the Leu/Val and Val/Val genotypes as compared with those possessing the Leu/Leu genotype (P<0.05). The PECAM‑1 Leu125Val polymorphism was shown to be associated with an increased risk of DVT and PECAM‑1 protein expression levels in venous vessels. In patients with DVT, the PECAM‑1 Leu/Val and Val/Val genotypes were associated with delayed thrombus resolution, as determined by thrombus scoring, as compared with that in patients possessing the Leu/Val genotype. In conclusion, the present study indicated that PECAM‑1 Leu125Val polymorphism and sPECAM‑1 levels may be associated with DVT.

View Figures

View References

1	Martinez C, Cohen AT, Bamber L and Rietbrock S: Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. Thromb Haemost. 112:255–263. 2014. View Article : Google Scholar : PubMed/NCBI
2	Monreal M, Barba R, Tolosa C, et al: Deep vein thrombosis and pulmonary embolism: the same disease? Pathophysiol Haemost Thromb. 35:133–135. 2006. View Article : Google Scholar : PubMed/NCBI
3	Nielsen JD: The incidence of pulmonary embolism during deep vein thrombosis. Phlebology. 28:29–33. 2013. View Article : Google Scholar : PubMed/NCBI
4	Blättler W and Partsch H: Leg compression and ambulation is better than bed rest for the treatment of acute deep venous thrombosis. Int J Angiol. 22:393–400. 2003.
5	Malone PC and Agutter PS: The aetiology of deep venous thrombosis. QJM. 99:581–593. 2006. View Article : Google Scholar : PubMed/NCBI
6	Schulz C, Engelmann B and Massberg S: Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J Thromb Haemost. 11:233–241. 2013. View Article : Google Scholar : PubMed/NCBI
7	Watson SP: Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. Curr Pharm Des. 15:1358–1372. 2009. View Article : Google Scholar : PubMed/NCBI
8	Brill A, Fuchs TA, Chauhan AK, et al: von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosisin mouse models. Blood. 117:1400–1407. 2011. View Article : Google Scholar :
9	von Brühl ML, Stark K, Steinhart A, et al: Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 209:819–835. 2012. View Article : Google Scholar : PubMed/NCBI
10	Jones CI, Moraes LA and Gibbins JM: Regulation of platelet biology by platelet endothelial cell adhesion molecule-1. Platelets. 23:331–335. 2012. View Article : Google Scholar
11	Berman ME and Muller WA: Ligation of platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31) on monocytes and neutrophils increases binding capacity of leukocyte CR3 (CD11b/CD18). J Immunol. 154:299–307. 1995.PubMed/NCBI
12	Cicmil M, Thomas JM, Leduc M, Bon C and Gibbins JM: Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood. 99:137–144. 2002. View Article : Google Scholar : PubMed/NCBI
13	Flynn KM, Michaud M, Canosa S and Madri JA: CD44 regulates vascular endothelial barrier integrity via a PECAM-1 dependent mechanism. Angiogenesis. 16:689–705. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kellermair J, Redwan B, Alias S, et al: Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. Blood. 122:3376–3384. 2013. View Article : Google Scholar : PubMed/NCBI
15	Robbins FM and Hartzman RJ: CD31/PECAM-1 genotyping and haplotype analyses show population diversity. Tissue Antigens. 69:28–37. 2007. View Article : Google Scholar : PubMed/NCBI
16	Novinska MS, Pietz BC, Ellis TM, Newman DK and Newman PJ: The alleles of PECAM-1. Gene. 376:95–101. 2006. View Article : Google Scholar : PubMed/NCBI
17	Listì F, Caruso C, Di Carlo D, et al: Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy. Rejuvenation Res. 13:237–241. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sahebkar A, Morris DR, Biros E and Golledge J: Association of single nucleotide polymorphisms in the gene encoding platelet endothelial cell adhesion molecule-1 with the risk of myocardial infarction: a systematic review and meta-analysis. Thromb Res. 132:227–233. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wei YS, Lan Y, Liu YG, Meng LQ, Xu QQ and Xie HY: Platelet-endothelial cell adhesion molecule-1 gene polymorphism and its soluble level are associated with ischemic stroke. DNA Cell Biol. 28:151–158. 2009. View Article : Google Scholar : PubMed/NCBI
20	Agnelli G, Gallus A, Goldhaber SZ, et al ODIXa-DVT Study Investigators: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 116:180–187. 2007. View Article : Google Scholar : PubMed/NCBI
21	Wolberg AS, Aleman MM, Leiderman K and Machlus KR: Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg. 114:275–285. 2012. View Article : Google Scholar :
22	Hasstedt SJ, Bezemer ID, Callas PW, et al: Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood. 114:3084–3091. 2009. View Article : Google Scholar : PubMed/NCBI
23	Jones CI, Garner SF, Moraes LA, et al: PECAM-1 expression and activity negatively regulate multiple platelet signaling pathways. FEBS Lett. 583:3618–3624. 2009. View Article : Google Scholar : PubMed/NCBI
24	Fang L, Wei H, Chowdhury SH, et al: Association of Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 (PECAM-1) gene & soluble level of PECAM-1 with coronary artery disease in Asian Indians. Indian J Med Res. 121:92–99. 2005.PubMed/NCBI
25	Goldberger A, Middleton KA, Oliver JA, et al: Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form. J Biol Chem. 269:17183–17191. 1994.PubMed/NCBI
26	Fornasa G, Groyer E, Clement M, et al: TCR stimulation drives cleavage and shedding of the ITIM receptor CD31. J Immunol. 184:5485–5492. 2010. View Article : Google Scholar : PubMed/NCBI
27	Moraes LA, Vaiyapuri S, Sasikumar P, et al: Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 122:3188–3196. 2013. View Article : Google Scholar : PubMed/NCBI
28	Eugenin EA, Gamss R, Buckner C, et al: Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J Leukoc Biol. 79:444–452. 2006. View Article : Google Scholar : PubMed/NCBI
29	Liao F, Ali J, Greene T and Muller WA: Soluble domain 1 of platelet-endothelial cell adhesion molecule (PECAM) is sufficient to block transendothelial migration in vitro and in vivo. J Exp Med. 185:1349–1357. 1997. View Article : Google Scholar : PubMed/NCBI
30	Pepene CE: Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction. Gynecol Endocrinol. 28:370–374. 2012. View Article : Google Scholar : PubMed/NCBI
31	Okoroh EM, Hooper WC, Atrash HK, Yusuf HR and Boulet SL: Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States 2003–2008. Am J Obstet Gynecol. 207:377.e1–e8. 2012. View Article : Google Scholar
32	Falati S, Patil S, Gross PL, et al: Platelet PECAM-1 inhibits thrombus formation in vivo. Blood. 107:535–541. 2006. View Article : Google Scholar
33	Privratsky JR, Paddock CM, Florey O, Newman DK, Muller WA and Newman PJ: Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity. J Cell Sci. 124:1477–1485. 2011. View Article : Google Scholar : PubMed/NCBI
34	Kahn SR: Post-thrombotic syndrome after deep venous thrombosis: risk factors, prevention, and therapeutic options. Clin Adv Hematol Oncol. 7:433–435. 2009.PubMed/NCBI